South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Sonoma Biotherapeutics is raising $264,999,947.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jeffrey Bluestone played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Sonoma Biotherapeutics
Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease safe, effective treatments as unique as each individual patient. Regulatory T cell therapies that harness a patients own immune cells, powerful next generation gene editing techniques and advanced manufacturing and quality assurance processes. Sonomas mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.

To learn more about Sonoma Biotherapeutics, visit http://www.sonomabio.com/

Contact:
Jeffrey Bluestone, President and Chief Executive Officer
415-992-6245
jbluestone@sonomabio.com
https://www.linkedin.com/in/jeffrey-bluestone-4399553/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved